A 2025 clinical trial reported that participants treated with ALZ-801 experienced approximately 18% less hippocampal atrophy than placebo-treated participants.
October 29, 2025
high
statistical
Brain atrophy (hippocampal volume) comparison between ALZ-801 and placebo in a 2025 trial.